'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy.
Fiche publication
Date publication
janvier 2021
Journal
Current drug targets
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The management of chronic conditions, above all rheumatic disease and diabetes, now incorporates a "treat to target" strategy where treatment aims to achieve objective outcomes. This is applicable in ulcerative colitis (UC) as well. Targets are demonstrated to prevent endorgan dysfunction, specifically bowel damage and its complications, and lastly colorectal cancer. Recently, the scientific community has tried to define further targets beyond those currently recommended, namely mucosal healing and clinical remission. Studies that prospectively investigated this approach in UC are scanty and a treat-to-target (T2T) algorithm is not routinely used in daily clinical practice.
Mots clés
Ulcerative colitis, histological healing, inflammation, mucosal healing, remission, target
Référence
Curr Drug Targets. 2021 ;22(1):117-125